NOT-AG-23-014: Notice to Extend the Expiration Date of PAR-20-309 "Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Notice to Extend the Expiration Date of PAR-20-309 "Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)”

Notice Number:

NOT-AG-23-014

Key Dates

Release Date:

March 16, 2023

Related Announcements

PAR-20-309 - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Issued by

National Institute on Aging (NIA)

Purpose

This Notice informs potential applicants that the expiration date for Funding Opportunity Announcement (FOA) PAR-20-309 "Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)" has been extended by one receipt cycle. The FOA now expires on May 8, 2024.

The following section under Part 1. Overview Information of PAR-20-309 has been modified:

Key Dates

Currently Reads: Expiration Date: January 8, 2024

Revised to Read: Expiration Date: May 8, 2024

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Pharmacological Interventions:

Laurie Ryan, Ph.D.
National Institute on Aging (NIA)
Division of Neuroscience (DN)
Telephone: 301-496-9350
Email: [email protected]

Non-Pharmacological Interventions:

Kristina McLinden, Ph.D.
National Institute on Aging (NIA)
Division of Neuroscience (DN)
Telephone: 301-496-9350
Email: [email protected]